Crucell Signs Second Exclusive License Agreement with Talecris Biotherapeutics

22-Dec-2008 - Crucell N.V. announced that it has signed a second exclusive, commercial license agreement with Talecris Biotherapeutics for an undisclosed and specific protein and the exclusive rights to produce that protein using the PER.C6® cell line. Crucell will receive an upfront payment of $1.5 million ...

Crucell announces European protein distribution deal with Talecris Biotherapeutics

04-Apr-2007 - Crucell N.V. announced a long-term distribution deal with North Carolina-headquartered Talecris Biotherapeutics, GmBH. Under the terms of the agreement, Crucell will serve as the exclusive distributor of Talecris' Prolastin® (alpha-1 proteinase inhibitor) in 9 Western European countries, ...

Talecris Continues Global Expansion into Europe

Talecris Biotherapeutics GmbH established as a wholly-owned sales and service organization to serve more than 15 European countries

04-Dec-2006 - Talecris Biotherapeutics Inc. announced the establishment of Talecris Biotherapeutics GmbH, its European headquarters in Frankfurt, Germany. Europe represents the second expansion in 2006 for the North Carolina-based biotherapeutics manufacturer, completing the next regional phase in the ...

Bausch & Lomb Licenses rPlasmin from Talecris Biotherapeutics for Ophthalmic Use

30-Aug-2006 - Bausch & Lomb and Talecris Biotherapeutics announced that Talecris has granted an exclusive worldwide license to Bausch & Lomb for recombinant Plasmin technology for use in ophthalmology. The companies will co-develop rPlasmin, a recombinant derivative of the human blood component Plasmin, which ...

Talecris Biotherapeutics' Manufacturing Processes Safeguard Against Avian Bird Flu

Processes assure inactivation of enveloped viruses like H5N1, preventing potential transmission through Talecris' therapeutic plasma proteins

14-Nov-2005 - Continuing its commitment to providing reliable supplies of the safest possible products, Talecris Biotherapeutics has confirmed its plasma collection and manufacturing processes significantly remove or inactivate enveloped viruses, such as those belonging to the influenza virus family, including ...

Talecris Biotherapeutics Strengthens its Executive Leadership Team

Alberto Martinez, M.D. selected as new CEO, John Hanson becomes new CFO, and Mel Asbury named SVP, Human Resources

31-Oct-2005 - After a focused and methodical search, Talecris Biotherapeutics has completed its executive leadership team with the appointments of three experienced, highly regarded executives. Alberto Martinez, M.D., has assumed the position of President and Chief Executive Officer; John Hanson has assumed ...